RxDoctor Payments Data

Matthew Lucas, DO

Dermatology · Fort Stewart, GANPI 1750677209

Payments from drug & device makers

$11,452in general payments, 2019–2025

Across 481 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$5K
  • Abbott$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • AbbVie$702
  • Novartis$461
  • Lilly USA, LLC$448
  • plus $3K from 22 others

What the payments were for

  • Consulting fees$1,95017%
  • Travel & lodging$1,0609%
  • Food & beverage$8,17971%
  • Education$2632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,452 in reported general payments places this provider in the 80th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$333,841
Medicare patients
1,107
Services billed
5,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab98$389,665
Cosentyx Sensoready (2 Pens)Secukinumab23$202,716
Cimzia (2 Pack)Certolizumab Pegol13$152,474
Dupixent SyringeDupilumab29$118,850
Cosentyx (2 Syringes)Secukinumab12$84,782
OpzeluraRuxolitinib Phosphate23$46,586
AdbryTralokinumab-Ldrm11$41,537
Clobetasol Propionate220$9,383
Tacrolimus81$9,046
Doxycycline Hyclate253$6,092
Fluocinonide102$4,891
Fluorouracil61$4,657
Triamcinolone Acetonide336$3,880
Ketoconazole166$2,642
Minocycline Hcl63$2,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$5,032$152,47413 claims
NovartisCosentyx (2 Syringes)$461$84,78212 claims
Incyte CorporationOpzelura$111$46,58623 claims
LEO Pharma Inc.Adbry$330$41,53711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 345 dermatology providers in Georgia.

Other dermatology in Fort Stewart

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →